TY - JOUR
T1 - Epidemiology, Etiology, and Treatment of Gastroparesis
T2 - Real-World Evidence From a Large US National Claims Database
AU - Ye, Yizhou
AU - Yin, Yu
AU - Huh, Susanna Y.
AU - Almansa, Cristina
AU - Bennett, Dimitri
AU - Camilleri, Michael
N1 - Funding Information:
Conflicts of interest The authors disclose the following: Yizhou Ye was an employee of Takeda Development Center Americas, Inc. at the time of the study, and is currently an employee of AbbVie Inc., North Chicago, Illinois. Yu Yin, Susanna Y. Huh, and Dimitri Bennett are employees of Takeda Development Center Americas, Inc. and receive stock or stock options. Cristina Almansa was an employee of Takeda Development Center Americas, Inc. and received stock or stock options at the time of the study, and is currently an employee of Ironwood Pharmaceuticals, Boston, Massachusetts. Michael Camilleri serves as an advisor to Takeda Development Center Americas, Inc., and has conducted research supported by Takeda Pharmaceuticals. He received no personal financial remuneration for this study. Funding This study was sponsored by Takeda Development Center Americas, Inc.
Funding Information:
Funding This study was sponsored by Takeda Development Center Americas, Inc.
Publisher Copyright:
© 2022 The Authors
PY - 2022/1
Y1 - 2022/1
N2 - Background & Aims: Although gastroparesis carries a considerable health care and patient burden, associated epidemiological data are limited. To provide new real-world evidence for gastroparesis, we estimated disease prevalence, and investigated patient demographics and disease etiology in a large US claims database. Methods: This retrospective, cross-sectional analysis used de-identified, longitudinal patient-level enrollment and billing data for adults from the Optum Clinformatics Data Mart database, a large US national administrative health insurance claims database. Prevalence was age-, sex-, and geographical region–standardized using the 2018 US census. Descriptive analyses of demographic and clinical variables and underlying disease etiologies were performed. Results: The overall standardized prevalence of gastroparesis was 267.7 (95% confidence interval [CI] 264.8–270.7) per 100,000 US adults, whereas prevalence of “definite” gastroparesis (individuals diagnosed within 3 months of gastric emptying scintigraphy testing with persistent symptoms for more than 3 months) was 21.5 (95% CI 20.6–22.4) per 100,000 persons. Patients with gastroparesis had an overall Charlson Comorbidity Index score of 4.2, indicating substantial comorbidity burden. The most frequently documented comorbidities were chronic pulmonary disease (46.4%), diabetes with chronic complication (37.3%), and peripheral vascular disease (30.4%). Patients most commonly had a diabetic etiology (57.4%; type 1, 5.7% and type 2, 51.7%), followed by postsurgical (15.0%), drug-induced (11.8%), and idiopathic (11.3%) etiologies. Conclusions: New evidence is provided regarding the prevalence, patient demographics, and etiology of gastroparesis in the US general population. Wider availability of reliable objective gastric emptying measures and further education of medical professionals in recognizing and diagnosing gastroparesis would benefit future studies and improve understanding of disease epidemiology.
AB - Background & Aims: Although gastroparesis carries a considerable health care and patient burden, associated epidemiological data are limited. To provide new real-world evidence for gastroparesis, we estimated disease prevalence, and investigated patient demographics and disease etiology in a large US claims database. Methods: This retrospective, cross-sectional analysis used de-identified, longitudinal patient-level enrollment and billing data for adults from the Optum Clinformatics Data Mart database, a large US national administrative health insurance claims database. Prevalence was age-, sex-, and geographical region–standardized using the 2018 US census. Descriptive analyses of demographic and clinical variables and underlying disease etiologies were performed. Results: The overall standardized prevalence of gastroparesis was 267.7 (95% confidence interval [CI] 264.8–270.7) per 100,000 US adults, whereas prevalence of “definite” gastroparesis (individuals diagnosed within 3 months of gastric emptying scintigraphy testing with persistent symptoms for more than 3 months) was 21.5 (95% CI 20.6–22.4) per 100,000 persons. Patients with gastroparesis had an overall Charlson Comorbidity Index score of 4.2, indicating substantial comorbidity burden. The most frequently documented comorbidities were chronic pulmonary disease (46.4%), diabetes with chronic complication (37.3%), and peripheral vascular disease (30.4%). Patients most commonly had a diabetic etiology (57.4%; type 1, 5.7% and type 2, 51.7%), followed by postsurgical (15.0%), drug-induced (11.8%), and idiopathic (11.3%) etiologies. Conclusions: New evidence is provided regarding the prevalence, patient demographics, and etiology of gastroparesis in the US general population. Wider availability of reliable objective gastric emptying measures and further education of medical professionals in recognizing and diagnosing gastroparesis would benefit future studies and improve understanding of disease epidemiology.
KW - Etiology
KW - Motility Disorders
KW - Observational Study
KW - Population-based
KW - Prevalence
UR - http://www.scopus.com/inward/record.url?scp=85120976993&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120976993&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2021.09.064
DO - 10.1053/j.gastro.2021.09.064
M3 - Article
C2 - 34624355
AN - SCOPUS:85120976993
SN - 0016-5085
VL - 162
SP - 109-121.e5
JO - Gastroenterology
JF - Gastroenterology
IS - 1
ER -